Popular medications approved for weight loss, diabetes, and heart disease may have health benefits beyond weight loss, and blood sugar control, but there are risks too.
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...
Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.
Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...